17 recruiting, 2 active not recruiting, 1 approved for marketing, 1 not yet recruiting. 13 Phase 2, 8 Phase 1, 6 Phase 3, 1 Phase 4.
By phase and status
Follow this drug Literature Review of Linvoseltamab trials Research Report on Linvoseltamab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)
Linvoseltamab - Multiple Myeloma | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 34 | 2026-10-01 | 2026-08-10 |
D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM
Isatuximab, Iberdomide, Bortezomib (B) - Multiple Myeloma | Phase 3 | Recruiting | Dana-Farber Cancer Institute | 720 | 2026-08-31 | 2026-10-09 |
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
Linvoseltamab, Tocilizumab - Relapsed/Refractory Multiple Myeloma (RRMM) | Phase 4 | Recruiting | Regeneron Pharmaceuticals | 30 | 2026-07-15 | 2026-09-25 |
A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Linvoseltamab, Bortezomib, Lenalidomide - Multiple Myeloma (MM) | Phase 2 / Phase 3 | Withdrawn | Regeneron Pharmaceuticals | | 2026-06-05 | 2026-06-18 |
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Linvoseltamab, Daratumumab - High Risk Smoldering Multiple Myeloma (HR-SMM) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 270 | 2026-05-21 | 2026-10-21 |
Horizon Two: HR NDMM (MMRC-100)
Bispecific Monoclonal Antibody and Triplet Therapy, Monoclonal Antibody with Stem Cell Transplant - High Risk Newly Diagnosed Multiple Myeloma | Phase 2 | Recruiting | Multiple Myeloma Research Consortium | 300 | 2026-04-30 | 2026-10-02 |
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
Linvoseltamab, REGN17372+Linvoseltamab - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 150 | 2026-03-26 | 2026-09-11 |
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Linvoseltamab, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2026-03-24 | 2026-09-16 |
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Linvoseltamab, Carfilzomib, Daratumumab - Relapsed and/or Refractory Multiple Myeloma (RRMM) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 915 | 2026-01-02 | 2026-10-21 |
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Linvoseltamab, Daratumumab, Lenalidomide - Multiple Myeloma | Phase 3 | Recruiting | European Myeloma Network B.V. | 1000 | 2025-12-23 | 2026-03-25 |
Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
Linvoseltamab, Lenalidomide - Multiple Myeloma | Phase 2 | Recruiting | Dickran Kazandjian, MD | 32 | 2025-12-02 | 2026-01-08 |
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
Linvoseltamab, REGN7945+Linvoseltamab - Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 186 | 2024-12-11 | 2026-08-05 |
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Linvoseltamab - Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM) | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 116 | 2024-09-16 | 2026-07-08 |
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
Linvoseltamab - Multiple Myeloma | Phase 2 | Recruiting | Dickran Kazandjian, MD | 150 | 2024-08-21 | 2026-08-18 |
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Linvoseltamab - Relapsed/Refractory Systemic Light Chain Amyloidosis | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 220 | 2024-08-07 | 2026-08-18 |
Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
linvoseltamab, dupilumab - Food Allergy | Phase 1 | Active not recruiting | Regeneron Pharmaceuticals | 6 | 2024-05-17 | 2026-06-26 |
A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma
Linvoseltamab - Smoldering Multiple Myeloma (SMM) | Phase 2 | Active not recruiting | Regeneron Pharmaceuticals | 40 | 2024-01-30 | 2026-04-13 |
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Linvoseltamab - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 149 | 2023-12-19 | 2026-05-13 |
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Linvoseltamab, Elotuzumab, Pomalidomide - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 410 | 2023-09-18 | 2026-10-07 |
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Linvoseltamab, Daratumumab, Carfilzomib - Multiple Myeloma | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 317 | 2022-08-17 | 2026-07-08 |
Showing 20 of 22. Sign in to see all of them.
Conditions studied
Multiple Myeloma (18) · Recurrence (3) · Smoldering Multiple Myeloma (3) · Cytokine Release Syndrome (1) · Food Hypersensitivity (1) · Monoclonal Gammopathy of Undetermined Significance (1) · SeSAME syndrome (1)
Sponsors
Regeneron Pharmaceuticals (15) · Dickran Kazandjian, MD (2) · Dana-Farber Cancer Institute (1) · European Myeloma Network B.V. (1) · Fred Hutchinson Cancer Center (1) · Medical College of Wisconsin (1) · Multiple Myeloma Research Consortium (1)
Countries
United States (16) · Spain (8) · United Kingdom (6) · Australia (5) · South Korea (5) · France (4) · Greece (4) · Belgium (3) · Germany (3) · Italy (3) · Japan (3) · Poland (3) · Taiwan (3) · Brazil (2) · Chile (2)
Top investigators
Dickran Kazandjian, MD (2) · Claudia Stege (1) · Clifton C. Mo, MD (1) · Hearn Jay Cho, MD, PhD (1) · Madhav Dhodapkar, MBBS (1) · Meera Mohan, MD (1) · Roberto Mina (1)
Results publications
PMID 38879802, PMID 41387038, PMID 41708325, PMID 42564571
NIH funding
2023 (4), 2025 (3)